The Ministry of Health approved clinical trials of a Ukrainian drug for the treatment of COVID-19
The Ministry of Health has authorized a clinical trial of a Ukrainian drug for the treatment of coronavirus disease (COVID-19).
The corresponding decree of the Ministry of Health No. 1038 of May 4 was published on the ministry’s website.
“Allow a clinical trial of a drug designed to take measures to prevent the onset and spread, localization and eradication of coronavirus disease (COVID-19),” said the document.
According to the annex to the prescription, a “multicenter randomized trial will be conducted to evaluate the efficacy of the drug Bioven, manufactured by Biofarma Plazma LLC, in the complex treatment of patients with pneumonia caused by a COVID-19 coronavirus infection / SARS-CoV-2”.
See also: COVID-19 treatment: Shimkiv spoke about the preparation of “Darnitsa” for the production of the drug
The research will be conducted at clinical hospital No. 17 in the city of Kiev (Department of Anesthesiology and Intensive Care); Belotserkovskaya City Hospital No. 3 (Infection Service III); Lviv Regional Infectious Clinical Hospital (intensive care unit and intensive care unit); Odessa City Infectious Disease Hospital (Infectious Boxing Unit No. 10) and Kiev City Clinical Hospital No. 4 (Department of Anesthesiology and Intensive Care).
As reported, as of May 5, 12,697 cases of COVID-19 coronavirus had been confirmed in Ukraine. 366 new cases were recorded per day. A total of 1,875 people have recovered since the start of the pandemic, 316 people have died.
According to the materials: ukrinform.ru